In the following sections, we discuss the clinical efficacy, safety, therapeutic strategies, challenges, and expectations of drugs related to the treatment of NSCLC with PD-1/PD-L1 and CTLA-4 as targets. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.